Imicilex (Cilastatin, Imipenem Anhydrate)

Imipenem inhibits penicillin‑binding proteins, blocking the final steps of bacterial cell‑wall synthesis and causing cell lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its plasma concentration and extending its antibacterial activity.

The dose of Imicilex is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosage regimens are established in clinical guidelines and should be followed as directed by a qualified healthcare professional.

Safety data for imipenem/cilastatin in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case and discuss potential risks with the patient.

To order Imicilex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Both imipenem/cilastatin (Imicilex) and meropenem belong to the carbapenem class and provide broad‑spectrum coverage against many Gram‑negative, Gram‑positive and anaerobic bacteria. Imipenem is often combined with cilastatin to prevent renal degradation, whereas meropenem does not require this inhibitor. Differences in stability, dosing frequency, and specific activity against certain resistant strains may influence the choice of agent based on local antibiograms and clinical judgment.

Imicilex should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Proper cold‑chain handling is essential to maintain drug potency and sterility.

Imicilex is given as an intravenous infusion. The powder is reconstituted with the appropriate diluent, then further diluted in compatible IV fluids as recommended by the manufacturer. Administration should be performed by qualified healthcare personnel, following aseptic technique and the infusion rate specified in the prescribing information.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome; and Clostridioides difficile‑associated colitis, which can lead to life‑threatening diarrhea. Prompt recognition and management of these reactions are critical.

Imicilex is contraindicated in individuals with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem antibiotics. Patients with severe renal impairment should not receive standard doses without appropriate adjustment, and those with a history of seizures should be used with caution. Clinicians must assess each patient’s medical history before initiating therapy.